The U.K. could be home to trials of cutting-edge cancer vaccines as soon as September, according to a German company.
A cancer sample is being held up for a photo at a research institute in Germany.
More than 10,000 cancer patients in the U.K. will be treated with personalized mRNA cancer treatments by the year 2030.
The same mechanism that the vaccines produced by Pfizer, BioNTech and Moderna use to train the body to recognize and fight the Covid-19 virus can be used to treat cancer.
The best possible treatments are available as soon as possible, and the trials for the cancer vaccines could begin as soon as September, according to the British health secretary.
The project is part of a larger partnership between the U.K. and Germany.
The company said it will establish a scientific research hub in Cambridge.
The U.K.'s rapid development of mRNA vaccines during the Covid-19 pandemic that showed "drug development can be accelerated without cutting corners" was praised by the co- founder and CEO of BioNTech.
Scientists have been working on vaccines for a long time. Traditional vaccines, which inject part or all of a virus into the body to provoke an immune response, work by injecting genetic instructions and allow the body to make part of the virus itself. The process is simpler and quicker than traditional methods and can be quickly edited to adapt to real world changes. A number of highly successful vaccines were built and successfully deployed using the technology from Moderna and Pfizer. Since the emergence of these vaccines during the Pandemic, pharma giants have been ramping up efforts to use them against other threats, like flu, HIV, shingles and cancer.
A whole new class of vaccine has been paved the way by the Pandemic. It could take a number of years until these are trialed and approved, as the emergency nature of the Covid-19 Pandemic fast tracked the process, which normally takes years. According to the founders of BioNTech, the cancer vaccine could be ready to use in patients by the year 2030. The early trial results of a vaccine that targets an aggressive type of skin cancer have been promising.
$24 billion. The Boston consulting group estimates how much the market will be worth by the year 2035. The majority of the vaccine will be preventative. Huge demand for Covid-19 vaccines, a market initially dominated by early-mover Moderna, Pfizer and BioNTech, puts a much higher value on the market now. It was worth $50 billion in 2021.
The billionaire CEO of BioNTech talks about the next era of vaccines.
The vaccine revolution is just getting started.
The UK would like to become a science superpower.
What is the next step in the development of vaccine technology?
All Rights Reserved © 2024
